Amicus Therapeutics Stock Forecast, Price & News

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last year. There are currently 7 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Amicus Therapeutics stock.
View analyst ratings for Amicus Therapeutics or view top-rated stocks.

Wall Street analysts have given Amicus Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Amicus Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Amicus Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Amicus Therapeutics.

Amicus Therapeutics will be holding an earnings conference call on Thursday, August 5th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 404-537-3406 with passcode "7374935".

Amicus Therapeutics, Inc. (NASDAQ:FOLD) posted its quarterly earnings results on Sunday, May, 9th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.24) by $0.01. The biopharmaceutical company had revenue of $66.40 million for the quarter, compared to the consensus estimate of $71.76 million. Amicus Therapeutics had a negative net margin of 95.05% and a negative trailing twelve-month return on equity of 80.85%.
View Amicus Therapeutics' earnings history.

Amicus Therapeutics' stock was trading at $8.05 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, FOLD stock has increased by 15.9% and is now trading at $9.33.
View which stocks have been most impacted by COVID-19.

Amicus Therapeutics issued an update on its FY 2021 earnings guidance on Tuesday, June, 8th. The company provided earnings per share (EPS) guidance of $- for the period. The company issued revenue guidance of $300 million-315 million, compared to the consensus revenue estimate of $312.64 million.

14 brokers have issued 12 month target prices for Amicus Therapeutics' stock. Their forecasts range from $13.00 to $31.00. On average, they anticipate Amicus Therapeutics' stock price to reach $18.83 in the next year. This suggests a possible upside of 101.9% from the stock's current price.
View analysts' price targets for Amicus Therapeutics or view top-rated stocks among Wall Street analysts.

21 employees have rated Amicus Therapeutics CEO John F. Crowley on Glassdoor.com. John F. Crowley has an approval rating of 48% among Amicus Therapeutics' employees. This puts John F. Crowley in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Amicus Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Exact Sciences (EXAS), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Novavax (NVAX), Repligen (RGEN), Neurocrine Biosciences (NBIX) and United Therapeutics (UTHR).
View all of FOLD's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amicus Therapeutics investors own include NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Sangamo Therapeutics (SGMO), Sarepta Therapeutics (SRPT), AbbVie (ABBV), Exelixis (EXEL), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO) and Novavax (NVAX).

Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD."

Amicus Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include New York State Common Retirement Fund (0.36%), Peregrine Capital Management LLC (0.27%), Rice Hall James & Associates LLC (0.24%), Alliancebernstein L.P. (0.14%), Asymmetry Capital Management L.P. (0.11%) and Brinker Capital Investments LLC (0.04%). Company insiders that own Amicus Therapeutics stock include Bradley L Campbell, Bradley L Campbell, Burke W Whitman, Daphne Quimi, Ellen Rosenberg, Hung Do, Jay Barth, John F Crowley, Lynn Dorsey Bleil, Margaret G Mcglynn, Michael Raab and Samantha Prout.
View institutional ownership trends for Amicus Therapeutics.

FOLD stock was sold by a variety of institutional investors in the last quarter, including Rice Hall James & Associates LLC, Arizona State Retirement System, New York State Common Retirement Fund, Zurcher Kantonalbank Zurich Cantonalbank , Alliancebernstein L.P., and Advisor Group Holdings Inc.. Company insiders that have sold Amicus Therapeutics company stock in the last year include Bradley L Campbell, Daphne Quimi, Hung Do, Jay Barth, John F Crowley, Margaret G Mcglynn, and Samantha Prout.
View insider buying and selling activity for Amicus Therapeutics or view top insider-selling stocks.

FOLD stock was purchased by a variety of institutional investors in the last quarter, including Asymmetry Capital Management L.P., Peregrine Capital Management LLC, Brinker Capital Investments LLC, and Advisors Asset Management Inc.. Company insiders that have bought Amicus Therapeutics stock in the last two years include Burke W Whitman, and Lynn Dorsey Bleil.
View insider buying and selling activity for Amicus Therapeutics or or view top insider-buying stocks.

Shares of FOLD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of FOLD stock can currently be purchased for approximately $9.33.

Amicus Therapeutics has a market capitalization of $2.48 billion and generates $260.89 million in revenue each year. The biopharmaceutical company earns $-276,850,000.00 in net income (profit) each year or ($1.04) on an earnings per share basis.

Amicus Therapeutics employs 483 workers across the globe.

The official website for Amicus Therapeutics is www.amicusrx.com.

Amicus Therapeutics is headquartered at 1 Cedar Brook Drive, Cranbury NJ, 08512.

Amicus Therapeutics' mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The biopharmaceutical company can be reached via phone at (215) 921-7600 or via email at [email protected]